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High-Mobility Group Box 1 Protein in Human and
Murine Skin: Involvement in Wound Healing
Stefania Straino1,8, Anna Di Carlo1,8, Antonella Mangoni1, Roberta De Mori1, Liliana Guerra2,
Riccardo Maurelli2, Laura Panacchia2, Fabio Di Giacomo2, Roberta Palumbo3, Cristiana Di Campli1,
Luigi Uccioli4, Paolo Biglioli5, Marco E. Bianchi6, Maurizio C. Capogrossi1 and Antonia Germani6,7
High-mobility group box 1 (HMGB1) protein is a multifunctional cytokine involved in inflammatory responses
and tissue repair. In this study, it was examined whether HMGB1 plays a role in skin wound repair both in
normoglycemic and diabetic mice. HMGB1 was detected in the nucleus of skin cells, and accumulated in the
cytoplasm of epidermal cells in the wounded skin. Diabetic human and mouse skin showed more reduced
HMGB1 levels than their normoglycemic counterparts. Topical application of HMGB1 to the wounds of diabetic
mice enhanced arteriole density, granulation tissue deposition, and accelerated wound healing. In contrast,
HMGB1 had no effect in normoglycemic mouse skin wounds, where endogenous HMGB1 levels may be
adequate for optimal wound closure. Accordingly, inhibition of endogenous HMGB1 impaired wound healing
in normal mice but had no effect in diabetic mice. Finally, HMGB1 had a chemotactic effect on skin fibroblasts
and keratinoyctes in vitro. In conclusion, lower HMGB1 levels in diabetic skin may play an important role in
impaired wound healing and this defect may be overcome by the topical application of HMGB1.
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INTRODUCTION
Skin wound repair is a complex process requiring the coordi-
nated interaction of numerous cell types. Growth factors and
cytokines released in the wound play a pivotal role in
orchestrating the regenerative process, which occurs through
three phases: inflammation, proliferation, and remodeling
(Martin, 1997). These events are finely balanced and any
alteration in their occurrence results in impaired wound
healing. In diabetes, there is evidence that the phases of
wound healing are deregulated. Decreased chemotaxis of
inflammatory cells into the wound leads to diminished
availability of growth factors important for effective wound
repair; excessive protease activity and increased microbial
load, together with the frequent co-existence of macro- and
microangiopathy, delay wound healing (Werner et al., 1994;
Shaw and Boulton, 1997; Doxey et al., 1998).
High-mobility group box 1 (HMGB1), a 214 amino-acid
protein with 99% amino-acid identity between rodent and
humans (Parkkinen et al., 1993; Maher and Nathans, 1996),
is a non-histone nuclear protein that binds into the minor
groove of DNA and, via this mechanism, is involved in the
regulation of gene transcription and in the modulation of
nucleosome accessibility (Bianchi et al., 1989; Giese et al.,
1992; Agresti and Bianchi, 2003). In addition to its role in the
nucleus, HMGB1 can be released into the extracellular
space. In the late phase of inflammation and in response to
various stimuli, including lipopolysaccharide, tumor necrosis
factor-a (TNF-a), or interleukin-1b (IL-1b), HMGB1 is secre-
ted by monocytes and macrophages (Wang et al., 1999;
Andersson et al., 2000; Scaffidi et al., 2002). The extracellular
protein acts as a cytokine by binding to the receptor for
advanced glycation end products (RAGE) and initiates a
positive feedback autocrine loop that maintains the inflam-
matory cascade. HMGB1 also elicits proinflammatory res-
ponses in endothelial cells by increasing the expression of
vascular adhesion molecules as well as secretion of cytokines
(TNF-a) and chemokines (IL-8 and MCP-1 (monocyte chemo-
tactic protein-1)) (Fiuza et al., 2003). High levels of HMGB1
have been detected in serum (Wang et al., 1999) and in the
synovial fluid (Kokkola et al., 2002; Taniguchi et al., 2003)
of patients with sepsis and rheumatoid arthritis, respectively.
Similarly, HMGB1 is increased in atherosclerotic lesions
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where it contributes to the inflammatory response (Kalinina
et al., 2004; Porto et al., 2006). Extracellular functions of
HMGB1 are not limited to inflammation. HMGB1 induces
neurite outgrowth in the developing nervous system as well
as neuronal differentiation of embryonic stem cells (Huttunen
et al., 2002) and smooth muscle cell chemotaxis (Degryse
et al., 2001). Moreover, HMGB1 is a strong chemoattractant
and mitogen for vessel-associated stem cells (mesoangio-
blasts) (Palumbo et al., 2004) and for endothelial precursor
cells (Chavakis et al., 2007). Recently, we demonstrated
that intracardiac HMGB1 injection in a mouse model of
myocardial infarction induced newly formed myocytes from
resident cardiac stem cells and functional recovery of the
infarcted hearts (Limana et al., 2005; Germani et al., 2007).
In this study, we examined the role of endogenous and
exogenously administered HMGB1 in skin tissue repair.
Lower levels of HMGB1 were detected in the skin of diabetic
patients and mice, where repair is impaired. Exogenous
HMGB1 directly applied to the wound accelerated healing
by enhancing vessel density and granulation tissue deposition
in diabetic mice but not in normal mice. HMGB1 inhibitors
delayed skin wound closure in normal mice, whereas they
had no effect in diabetic mice. Both skin fibroblasts and
keratinocytes migrated in vitro in response to HMGB1. These
results suggest that HMGB1 is required for skin regeneration
and that its low level in diabetic patients and in mice may
contribute to delayed wound healing.
RESULTS
HMGB1 in normal and diabetic skin wounds
The distribution of HMGB1 during skin wound healing was
investigated in skin biopsies from normoglycemic and
diabetic patients. Immunohistochemical analysis revealed
that HMGB1 distribution both in non-diabetic and diabetic
human skin was restricted to the nucleus of both epidermal
and dermal cells (Figure 1a). To address whether HMGB1
distribution was modified in chronic, non-healing wounds,
skin biopsies were taken from the edge of the ulcers of
diabetic and normoglycemic patients. In non-healing ulcers,
HMGB1 was localized in the cytoplasm of epidermal cells
(Figure 1a) without difference in its localization between
diabetic and normoglycemic skin lesions. HMGB1 cytoplas-
mic relocalization represents a signal for its secretion in
inflammatory cells stimulated either with lipopolysaccharide
Normoglycemic Diabetic
Ng Db
HMGB1
HMGB1
9
8
7
6
5
4
3
2
1
0
0 0
0
1
2
∗
∗3
4
5
3 5 73
Ng
Db
5
∗
7
Fo
ld
 in
cr
ea
se
HMGB1
RAGE
RAGE
RAGE
α-Tubulin
α-Tubulin
Ng
C C3d 3d5d 5d7d 7d
Db
Healthy skin Healthy skin
1.0
Ng
∗
Db
HMGB1 RAGE
0.8
0.6
0.4
0.2
0
Fo
ld
 v
a
ria
tio
n
Perilesional region Perilesional region
a
b
e f
c d
Figure 1. HMGB1 expression in normal and diabetic skin. (a) Representative immunohistochemical staining for HMGB1 in human normoglycemic and diabetic
skin in the absence of skin lesions (healthy skin) and in the peri-lesional region (n¼ 4). Bar¼ 50mm. (b) Immunofluorescence analysis showing HMGB1
localization in unstimulated (left panel) and TNF-a-stimulated (right panel) human fibroblasts. Bar¼ 50 mm. (c–e) Western blot analysis to detect HMGB1
and RAGE levels in (c, d) normoglycemic (Ng) and diabetic (Db) human healthy skin extracts, and (e, f) in normoglycemic (Ng) and diabetic (Db) mouse skin
prior to (C) and at 3, 5 and 7 days after wounding. To normalize loading, filters were also probed with anti-a-tubulin mAb. (d, f) Average results, normalized
to a-tubulin, of HMGB1 and RAGE densitometric analyses for the experimental protocols shown in (c) and (e), respectively (n¼ 4, *Po0.05 vs their
corresponding Ng values). Values are expressed as the mean±SE.
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or inflammatory mediators, that is, TNF-a (Wang et al., 1999;
Bonaldi et al., 2003). To evaluate whether inflammatory
stimuli at the wound site may have a similar effect on dermal
cells, HMGB1 distribution was analyzed in isolated human
fibroblasts and keratinocytes exposed to TNF-a. In both cell
types, HMGB1 was detected in the cell nucleus in the
absence of stimulation (Figure 1a and data not shown); TNF-a
induced HMGB1 cytoplasmic translocation in skin fibroblasts
(Figure 1b), whereas its distribution was not affected in
keratinocytes (data not shown). Furthermore, HMGB1 was
not detected in the conditioned medium of TNF-a-treated
human fibroblasts (data not shown).
HMGB1 protein levels were then evaluated in human and
mouse normoglycemic and diabetic skin. In the absence of
lesions, HMGB1 protein levels were lower in diabetic than in
normoglycemic human skin (Figure 1c and d), and a trend in
the reduction of HMGB1 levels was also detected in diabetic
mouse skin (Figure 1e and f). Both in normoglycemic and
in diabetic mice, skin injury induced a transient increase of
HMGB1; however, at day 3 after wounding, HMGB1 levels
were higher in normoglycemic mice compared to their
diabetic counterpart (Figure 1e and f). The HMGB1 receptor
RAGE strongly increased in diabetic skin compared with
normoglycemic skin at day 3 after wounding, and returned to
control levels by day 7 (Figure 1e and f).
HMGB1 administration promotes wound healing in diabetic
mice
As HMGB1 levels were reduced in diabetic skin, in these
experiments it was examined whether HMGB1 topical appli-
cation to murine diabetic skin wounds promoted wound
closure. Wound healing in diabetic mice was delayed as
expected (Figure 2a) (Goodson and Hung, 1977; Romano Di
Peppe et al., 2002). A single dose of 200, 400, and 800ng
HMGB1 was applied to the wound. In response to 200 and
400ng HMGB1, wound closure was accelerated compared
to wounds treated either with saline or 800 ng of protein
(Figure 2b). Wound areas shrank, at day 3, by 37.6±5.3% in
400 ng HMGB1-treated mice and by 13±4% in saline-
treated mice (Figure 2b); wound closure was 62.7±5 vs
44.5±1.9% at day 5 and 70±4.8 vs 63.3±2% at day 6
(Figure 2b). The effect of HMGB1 was compared to that
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Figure 2. Effect of topical administration of HMGB1 in wound healing. Kinetics of skin wound healing in (a) normoglycemic and diabetic mice in the
absence of any treatment (12 mice/group; *Po0.003 vs control) and (b) in diabetic mice that received topical application of HMGB1 (n¼ 10 mice per HMGB1
200ng group, n¼ 6 mice/HMGB1 400 and 800 ng groups) or saline (n¼ 28, mice; **Po0.001 and *Po0.01 vs saline; wPo0.05 vs HMGB1 200 ng). Lower
panel: representative pictures of diabetic wounds treated either with saline solution or a single dose of HMGB1 (400 ng). (c) Analysis of wound healing in
diabetic mice treated either with HMGB1 (n¼4 mice per group, 400 ng; *Po0.05 vs saline group) or PDGF-BB (n¼ 4 mice per group, PDGF-BB 400 ng;
wPo0.05 vs saline group). (d) Kinetics of skin wound healing in normoglycemic and mice treated either with HMGB1 (200 ng) or saline solution (n¼6 mice
per group). Results are presented as percentage of wound closure, that is, wound area at different times after wounding per wound area at time 0, and
values expressed as the mean±SE.
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obtained with platelet-derived growth factor BB (PDGF-BB),
a growth factor well known to induce wound healing
(Greenhalgh et al., 1990), and also approved for clinical
use in the treatment of skin ulcers. Both PDGF-BB and
HMGB1 applied to wounds in a single dose of 400 ng showed
a comparable effect in wounded area reduction (Figure 2c).
In normoglycemic mice, HMGB1 application to the wound
site did not significantly modify wound healing (Figure 2d).
Inhibition of endogenous HMGB1 impairs wound healing in
normoglycemic mice
The lower HMGB1 level in diabetic mice and the improvement
in wound healing observed in response to HMGB1 in diabetic
mice, but not in normoglycemic mice, suggested that
normoglycemic mice may already have an optimal amount
of HMGB1 for wound closure. Thus, we tested the effect of
HMGB1 blockade in normoglycemic mice using the HMGB1-
DNA binding A box (BoxA), a truncated form of the protein that
acts as a competitive antagonist by inhibiting HMGB1 binding
to its receptor RAGE (Kokkola et al., 2003; Yang et al., 2004).
BoxA was administered topically in the full excisional wound
every 2 days from day 0 to day 14 after wounding. Between
days 3 and 7 after wounding, BoxA slowed down wound
closure in normal mice (Figure 3a). At day 3, wound areas were
reduced by 29±4.6 and 14.6%±2.6% in saline- and BoxA-
treated mice, respectively. Statistically significant differences in
wound closure persisted at day 5 (54.6±5.4 vs 37.6±4.1%)
and at day 6 (69.3±4.2 vs 52.2±4.6%) (Figure 3a). In contrast,
no delay in wound closure in response to BoxA was observed
in diabetic mice (Figure 3b). Similar results were obtained
both in diabetic and normoglycemic mice with glycyrrhizin,
a different HMGB1 inhibitor (Sitia et al., 2006) (Figure S1).
Taken together, these data suggest that endogenous
HMGB1 is adequate for wound healing in normoglycemic
mice, but is not sufficient in diabetic mice.
HMGB1 promotes granulation tissue formation and increases
vessel density in diabetic skin wounds
Histologic evaluation of diabetic wounds performed 5 days
after wounding revealed that HMGB1 administration (400 ng)
significantly increased wound re-epithelialization, whereas
the administration of BoxA had no effect (Figure 4a). Granu-
lation tissue area measurement at day 5 after wound and
HMGB1 treatment revealed an increase in granulation tissue
vs saline-treated wounds, and the amount of granulation
tissue was comparable to that present in normoglycemic
mouse wounds treated with saline (Figure 4b and c).
In contrast, the granulation tissue area in BoxA-treated
wounds was similar to that observed in saline-treated wounds
(Figure 4b). Notably, wounds that received saline solution
appeared poorly cellularized with low amount of deposited
collagen (Figure 4c). Morphometric analysis indicated that
the density of arterioles 4–41 mm in diameter, identified by
staining with antibodies against anti-smooth muscle actin and
von Willebrand factor, was significantly increased in diabetic
HMGB1-treated wounds compared both with saline- or
BoxA-treated wounds (16.8±1.5 vs saline 8.8±2mmmm3)
(Figure 4d–f). The enhanced vascularization observed in
HMGB1-treated wounds was not associated with increased
stem cell recruitment; c-kitþ and CD34þ cell number was
similar in HMGB1- and saline-treated diabetic wounds (data
not shown).
HMGB1 has a chemotactic effect on fibroblasts and
keratinocytes
As rapid induction of keratinocyte and fibroblast migration
and proliferation into wounds are necessary for tissue repair,
we examined HMGB1’s ability to modulate these cells’ func-
tion in vitro. Under our experimental conditions, HMGB1
promoted fibroblast and keratinocyte migration in a concen-
tration-dependent manner. Fibroblast and keratinocyte peak
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Figure 3. Effect of HMGB1 inhibition on wound healing. Analysis of wound closure in normoglycemic (a) and diabetic (b) mice treated either with a
saline solution or BoxA (1 mg). BoxA was administered to wounds every 2 days. Lower panels: Representative pictures of wound healing in saline solution-
and BoxA-treated normoglycemic (a) and diabetic mice (b) (n¼15 mice per saline groups and n¼ 10 mice per BoxA-treated groups. **Po0.05 and *Po0.01
vs BoxA). Values are expressed as the mean±SE.
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chemotactic response was achieved with 100 and 10ngml1
HMGB1, respectively (Figure 5a and b). PDGF-BB (15ngml1)
and epidermal growth factor (EGF, 10ngml1) were used as
positive controls for fibroblast and keratinocyte migration
assays, respectively (Figure 5a and b). In additional experi-
ments, we examined HMGB1 chemotactic effects on fibro-
blasts and keratinocytes isolated from diabetic patients
(Figure 5c and d). We were limited by the difficulty of
obtaining a large number of fibroblasts and keratinocytes
from diabetic biopsies, and we therefore tested migration only
in response to 100 and 10ngml1 HMGB1, respectively.
Under all conditions tested, migration of diabetic fibroblasts
and keratinocytes was markedly impaired compared to their
normoglycemic counterparts (Figure 5a and b) (Lerman et al.,
2003). However, as in normoglycemic cells, 100ngml1
HMGB1 induced a B3-fold increase in the number of
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Figure 4. Effect of HMGB1 on re-epithelialization, granulation tissue, and vessel density. (a) HMGB1 administration to diabetic wounds reduced the
epithelial gap (left panel) and enhanced re-epithelialization (right panel) at day 5 after injury (n¼6 mice per group, *Po0.05 vs saline and BoxA-treated
wounds). (b) HMGB1, but not BoxA, enhanced granulation tissue area. Central sections of wound area were examined at day 5 after wounding (n¼ 6 mice per
group; *Po0.05 vs db saline-treated wounds; **Po0.01 vs normoglycemic saline-treated wounds). Values are expressed as the mean±SE. (c) Representative
images of the granulation tissue area stained with hematoxylin–eosin (H&E) (left panels) and of the collagen deposition stained with Masson’s Trichrome
(right panels) in normoglycemic wounds which received saline (upper panel) and in diabetic wounds treated either with saline (middle panel) or HMGB1
(lower panel). Bar¼ 50 mm. (d) Arteriole length density in 5 days of diabetic wounds measured by smooth muscle actin staining (n¼ 6 mice per group;
*Po0.01). Values are expressed as the mean±SE. (e, f) Representative images of vessels stained with smooth muscle actin (red fluorescence) (e) and
vWF (f) (green fluorescence). Bar¼ 25mm.
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migrating fibroblasts (Figure 5c). Keratinocytes from diabetic
patients migrated in response to EGF, whereas there was no
significant chemotactic effect of 10ngml1 HMGB1 on these
cells (Figure 5d). HMGB1-induced migration of both normo-
glycemic fibroblasts and keratinocytes was inhibited by BoxA
(Figure 5e and f). It is noteworthy that BoxA had no inhibitory
effect on PDGF-BB- and EGF-mediated fibroblast and keratino-
cyte migration, respectively (Figure 5e and f). Finally, HMGB1
(10, 100, and 200ngml1) did not significantly affect fibroblast
and keratinocyte proliferation, as it failed to increase cell
number vs control after 24 and 48hours in culture (data not
shown).
DISCUSSION
HMGB1 is a multifunctional cytokine known to play a
key role in inflammation. Recently, it has been shown that
HMGB1 administration to skeletal muscle induces stem cell
recruitment in the absence of damage (Palumbo et al., 2004)
and regeneration either after acute hindlimb ischemia
(De Mori et al., 2007) or myocardial infarction (Limana
et al., 2005) through a mechanism that involves activation of
resident stem cells. These experimental evidences prompted
us to investigate HMGB1’s role in cutaneous wound healing.
Further, as skin wound repair is impaired in diabetes, we
examined HMGB1 expression and function both in normo-
glycemic and diabetic human and mice skin. HMGB1 is
expressed in skin cells: it is located in the nucleus of
normoglycemic and diabetic epidermal cells and, in the
presence of skin ulcers, it accumulates in the cytoplasm of
cells located in the peri-lesional regions. The role and mecha-
nisms of the cytoplasmic redistribution of HMGB1 in these
cells is currently not understood. During wound repair,
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Figure 5. Effect of HMGB1 on human fibroblast and keratinocyte migration. (a, b) Normoglycemic human fibroblasts and keratinocytes were subjected
to chemotaxis assays with the indicated concentrations of HMGB1; PDGF-BB (15 ngml1) and EGF (10 ngml1) were used as positive controls for fibroblast
and keratinocyte migration, respectively. DMEM containing 0.1% BSA was used as negative control (). Optimal HMGB1 concentrations were 100 and
10ngml1 for fibroblasts and keratinocytes, respectively. (c, d) Chemotactic activity of 100 and 10 ngml1 HMGB1 on diabetic fibroblasts and keratinocytes,
respectively. Data were obtained from four independent experiments performed in triplicate (* and **Po0.01 and Po0.001, respectively, vs negative
control). (e) Fibroblasts were induced to migrate in the presence of 100 ngml1 of HMGB1 alone or in the presence of BoxA (500 ngml1). (f) Keratinocytes
migrated in response to 10 ngml1 HMGB1 and BoxA (50 ngml1) blocked this effect. The data are expressed either as number of migrated cells or as the
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several pro-inflamamtory cytokines are upregulated
(Grellner, 2002); among these cytokines, TNF-a has been
shown to promote HMGB1 secretion from monocytes. It is
noteworthy that in TNF-a-stimulated human fibroblasts,
HMGB1 was accumulated in the cytoplasm, but was not
detected in the culture medium. Nevertheless, it is possible
that HMGB1 secretion from fibroblasts may occur in vivo
where the activation of multiple pathways as well as enhan-
ced membrane permeability, which occurs during necrosis,
could direct the protein to the extracellular space.
In this study, it was found that HMGB1 levels were redu-
ced in the skin of both diabetic humans and mice. In mouse
skin wounds, HMGB1 and RAGE expression increased; in
normoglycemic animals, HMGB1 and RAGE expression
peaked 3 days after wounding and were back to baseline
by day 5. A similar pattern of HMGB1 and RAGE expression
was detected during wound repair in diabetic mice, although
these mice displayed lower HMGB1 and higher RAGE levels
compared to their normoglycemic counterparts. Therefore,
we suggest that reduced HMGB1 in diabetic skin may
account, at least in part, for the altered wound healing
process in diabetes. In agreement with this hypothesis,
blocking HMGB1 either with competitor BoxA or glycyr-
rhizin slowed wound healing in normoglycemic mice,
whereas HMGB1 administration enhanced wound healing
in diabetic mice. Furthermore, HMGB1 administration
did not significantly modify wound closure in normal mice,
where endogenous HMGB1 levels may already be optimal.
There are several mechanisms by which HMGB1 may
promote skin wound repair. HMGB1 induces human fibro-
blast and keratinocyte migration; such migration is reduced
in cells from diabetic patients. Although HMGB1 has been
shown to have a proliferative effect on murine 3T3 fibroblasts
(Zimmermann et al., 2004), proliferation of skin fibroblast
and keratinocyte was not affected by HMGB1 treatment.
HMGB1 also induces angiogenesis in vitro and in vivo
(Schlueter et al., 2005; Mitola et al., 2006). Indeed, HMGB1
increased the density of arterioles during the healing of
diabetic wounds, and this effect likely contributed to
increased granulation tissue formation. This process most
likely did not involve stem cell recruitment to the wound
site, as neither endothelial precursor cells expressing
CD34 antigen nor bone marrow-derived cells expressing
c-kit increased after HMGB1 administration to diabetic
wounds. Finally, HMGB1 may act on macrophages, whose
role in wound repair is well established (DiPietro, 1995;
Doxey et al., 1998; Wetzler et al., 2000; Zykova et al., 2000).
Our results also suggest that HMGB1 topical administra-
tion to diabetic wounds may have a therapeutic potential.
However, at high concentration, HMGB1 has detrimental
effects; it exacerbates inflammation and it is known to
contribute to several inflammatory and infectious disorders
(Ulloa and Messmer, 2006). Indeed, 500 mg of HMGB1
delivered intraperitoneally causes shock in mice (Wang et al.,
1999), whereas intra-tracheal administration of 10–100 mg
HMGB1 produces inflammatory injury including neutrophil
accumulation and lung edema (Ulloa and Messmer, 2006).
The amount of HMGB1 that showed a beneficial effect in
wound healing, 200–800 ng, is well below the HMGB1 level
known to have a detrimental effect and is in the concentra-
tion range that has been shown to induce skeletal muscle
and cardiac regeneration following myocardial infarction
(Limana et al., 2005; De Mori et al., 2007). In conclusion,
the results of this study show that endogenous HMGB1 is
critical for skin tissue repair and that the reduced levels of
HMGB1 in diabetic skin may impair wound healing; this
specific defect can be corrected by exogenous HMGB1
topical administration.
MATERIALS AND METHODS
Reagents
Expression and purification of both HMGB1 and its truncated form,
BoxA, were performed by HMGBiotech (Milan, Italy). Endotoxins
were removed by passage through Detoxy-Gel columns (Pierce
Biotechnology Inc., Rockford, IL). Recombinant HMGB1 was diluted
in PBS and stored at 80 1C. Glycyrrhizin was from Minophagen
Pharmaceutical (Tokyo, Japan). PDGF-BB and EGF were purchased
by R&D Systems (Minneapolis, MN).
Human studies—skin biopsies, cell isolation, and culture
After Local Ethical Committee approval and signed informed
consent, skin biopsies were obtained from normoglycemic controls
and type II diabetic patients aged 45–70 years. The study was
conducted according to the Declaration of Helsinki Principles.
A punch biopsy, 4mm in diameter, was performed under local
anesthesia in the peri-lesional area of the skin ulcer or in the skin
edge of a surgical incision during routine surgery. For fibroblast
isolation, biopsies were seeded on 6-mm-diameter tissue culture
dishes containing DMEM with 10% fetal bovine serum (Euroclone
Inc., Milan, Italy), 20mM glutamine, 100Uml1 penicillin, and
100mgml1 streptomycin (Gibco BRL, Paisley, UK). Fibroblasts
started growing out of the explants after 7–10 days and became
confluent within 3–5 weeks. Normal and diabetic epidermal
keratinocytes were cultured on a feeder layer of lethally irradiated
3T3-J2 cells as described (Pellegrini et al., 1999). Cells were used at
passages 2–4.
Immunofluorescence and HMGB1 detection in the culture
medium
Human fibroblasts were kept in DMEM overnight and then TNF-a
(50 ngml1) was added at the culture medium for 20 hours. Cells
were fixed in PBS with 4% paraformaldehyde and permeabilized in
PBS with 0.1% Triton X-100. Coverslips were rinsed and blocked
10minutes in PBS with 0.2% BSA before incubation with antibodies.
Fixed cells were incubated with primary antibody anti-HMGB1
polyclonal antibody (1 mgml1) followed by incubations with goat
anti-rabbit antibody coupled to fluorescein isothiocyanate (FITC)
(1:40). The coverglasses were mounted and analyzed with a Zeiss
microscope equipped for epifluorescence. HMGB1 detection in the
culture medium was performed either by western blot or ELISA assay
(Oxford Biosystems, Oxford, UK).
Migration assays
Chemotaxis was performed in 48-microwell chemotaxis chambers
(Neuroprobe, Cabin John, MD) using 8 mm pore size polycarbonate
filters (Costar Scientific Corporation, Cambridge, MA) coated with
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murine collagen type IV (Becton-Dickinson, Bedford, MA) (Supple-
mentary Materials and Methods).
Animal skin wound model
CD1 male mice were obtained from Charles River (Calco, Lecco,
Italy). Mice were rendered diabetic by intraperitoneal injection of a
single dose of streptozotocin (200mg per kg weight, Sigma-Aldrich,
St Louis, MO). After 2 weeks, glycemia was measured, and animals
with a blood glucose level of 200–400mg per 100ml were selected
for further studies. Three weeks later, mice were anesthetized with
an intraperitoneal injection of 2.5% Avertin (Sigma) (100% Avertin:
10 g 2,2,2-tribromoethyl alcohol in 10ml tert-amyl alcohol). Their
dorsum was clipped free of hair and a full-thickness wound of
3.5mm diameter was created using a biopsy punch. HMGB1 was
applied at the indicated concentration in 20 ml of saline solution,
directly in the wound area at time 0, in a single dose. Another group
of diabetic and non-diabetic mice was treated by placing 20 ml of
saline solution on the wound. The HMGB1 inhibitor BoxA and
glycyrrhizin were administered in the wound area at the concentra-
tion of 1 and 250 mg per mouse in 20 ml of PBS, respectively.
To compare the rate of wound closure between HMGB1-treated and
saline-treated mice, animals were photographed at day 0, 3, 5, 6, 7,
10, and 14 after treatment.
At different time points after treatment, pictures were digitally
processed and wound areas were calculated using the KS300
system (Zeiss, Jena GmbH, Germany). For each sample, the rate of
the healing process was measured as a ratio of the area at each time
point divided by the area at time 0 (that is, immediately after the
wound). All experimental procedures complied with the Guidelines
of the Italian National Institutes of Health, with the Guide for the
Care and Use of Laboratory Animals (Institute of Laboratory Animal
Resources, National Academy of Sciences, Bethesda, MD) and were
approved by the Institutional Animal Care and Use Committee.
Histology and wound analysis
Human and mouse biopsies were fixed in formalin and embedded in
paraffin (Bio-plast special; melting point 52–54 1C). For immunohis-
tochemical staining, 3-mm-thickness sections incubated with specific
antibodies (Supplementary Materials and Methods).
Hematoxylin–eosin staining was performed to quantify granula-
tion tissue as described (Romano Di Peppe et al., 2002). The
epithelial gap, which represents the distance between the leading
edge of migrating keratinocytes, was measured by hematoxylin–
eosin staining and reported in millimeter. The percent of re-
epithelialization was calculated with the following formula:
%Re epithelialization ¼ 1 Wound sizeOriginalwound size
h i
100 (Cheng et al.,
2007).
Data collections and statistics
Immunohistochemistry analyses were examined blindly. Compa-
risons among different groups for continuous variables were
carried out by analysis of variance. Statistical significance
between two measurements was evaluated by a two-tailed unpaired
Student’s t-test. A P-value o0.05 was considered statistically
significant.
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